Form 4: Curis Inc. CEO James E. Dentzer Receives Stock Option Grant Following Shareholder Approval
SEC Form 4 Filing
Curis Inc. CEO James E. Dentzer was granted a stock option to purchase 100,000 shares of common stock after shareholders approved the Fifth Amended and Restated 2010 Stock Incentive Plan.
Summary
- On May 21, 2024, Curis Inc. CEO James E. Dentzer received a stock option grant for 100,000 shares.
- The grant was contingent upon shareholder approval of the Fifth Amended and Restated 2010 Stock Incentive Plan, which occurred on May 21, 2024.
- The option has an exercise price of $11.62 per share and expires on January 18, 2034.
- The option vests as to 25% of the shares on January 19, 2025, and then 6.25% each quarter until January 19, 2028.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options to the CEO is a standard practice and aligns interests with shareholders. The successful shareholder approval is also a positive sign.
Positives
- The stock option grant aligns the CEO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the option.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are common in the biotech industry to incentivize performance.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical components of such grants, designed to align executive interests with long-term shareholder value.
Stakeholder Impact
- Shareholders: The grant aligns the CEO's interests with increasing shareholder value.
- Employees: The grant may improve morale by demonstrating confidence in the company's leadership.
Key Dates
| Date | Description |
|---|---|
| January 19, 2024 | Compensation Committee approved the option grant contingent on shareholder approval. |
| May 21, 2024 | Date of earliest transaction and shareholder approval of the Fifth Amended and Restated 2010 Stock Incentive Plan. |
| May 23, 2024 | Date of Form 4 filing. |
| January 19, 2025 | First vesting date for 25% of the option shares. |
| January 19, 2028 | Final vesting date for the option shares. |
| January 18, 2034 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.